A peroxisome proliferator-activated receptor-γ agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells

Cancer Research

Volumn 63, Issue 8, 2003, Pages 1914-1919

  Herbert, Brittney Shea ^a   Pearce, Virginia P ^a   Hynan, Linda S ^a   LaRue, Denise M ^a   Wright, Woodring E ^a   Kopelovich, Levy ^b   Shay, Jerry W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SULINDAC SULFIDE;

ADULT; ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; CELL DEATH; CELL IMMORTALIZATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TELOMERE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; BREAST; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; LI-FRAUMENI SYNDROME; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TELOMERE; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0037447175     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Wright, W. E., Pereira-Smith, O. M., and Shay, J. W. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol. Cell. Biol., 9: 3088-3092, 1989.
2. Hara, E., Tsurui, H., Shinozaki, A., Nakada, S., and Oda, K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts. Biochem. Biophys. Res. Commun., 179: 528-534, 1991.
3. Shay, J. W., Wright, W. E., and Werbin, H. Defining the molecular mechanisms of human cell immortalization. Biochim. Biophys. Acta, 1072: 1-7, 1991.
4. Wright, W. E., and Shay, J. W. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr. Opin. Genet. Dev., 11: 98-103, 2001.
5. Harley, C. B., Futcher, A. B., and Greider, C. W. Telomeres shorten during aging of human fibroblasts. Nature (Lond.), 345: 458-460, 1990.
6. Campisi, J., Kim, S. H., Lim, C. S., and Rubio, M. Cellular senescence, cancer and aging: the telomere connection. Exp. Gerontol., 36: 1619-1637, 2001.
7. de Lange, T. Protection of mammalian telomeres. Oncogene, 21: 532-540, 2002.
8. Blackburn, E. H. Structure and function of telomeres. Nature (Lond.), 350: 569-573, 1991.
9. Blackburn, E. H. Telomeres: no end in sight. Cell, 77: 621-623, 1994.
10. Greider, C. W. Mammalian telomere dynamics: healing, fragmentation shortening and stabilization. Curr. Opin. Genet. Dev., 4: 203-211, 1994.
11. Harley, C. B. Telomere loss: mitotic clock or genetic time bomb? Mutat. Res., 256: 271-282, 1991.
12. Sedivy, J. M. Can ends justify the means?: telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells. Proc. Natl. Acad. Sci. USA. 95: 9078-9081, 1998.
13. Blasco, M. A., Lee, H. W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., and Greider, C. W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell, 91: 25-34, 1997.
14. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Wash. DC), 266: 2011-2015, 1994.
15. Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., and Reddel, R. R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med., 3: 1271-1274, 1997.
16. Vaziri, H., and Benchimol, S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol., 8: 279-282, 1998.
17. Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. Extension of life-span by introduction of telomerase into normal human cells. Science (Wash. DC), 279: 349-352, 1998.
18. Shay, J. W., and Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer, 33: 787-791, 1997.
19. Carey, L. A., Hedican, C. A., Henderson, G. S., Umbricht, C. B., Dome, J. S., Varon, D., and Sukumar, S. Careful histological confirmation and microdissection reveal telomerase activity in otherwise telomerase-negative breast cancers. Clin. Cancer Res., 4: 435-440, 1998.
20. Yashima, K., Milchgrub, S., Gollahon, L. S., Maitra, A., Saboorian, M. H., Shay, J. W., and Gazdar, A. F. Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma. Clin. Cancer Res., 4: 229-234, 1998.
21. Shay, J. W., Tomlinson, G., Piatyszek, M. A., and Gollahon, L. S. Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni Syndrome. Mol. Cell. Biol., 15: 425-432, 1995.
22. Herbert, B-S., Wright, A. C., Passons, C. M., Ali, I., Wright, W. E., Kopelovich, L., and Shay, J. W. Effects of Chemopreventive and anti-telomerase agents on the spontaneous immortalization of breast epithelial cells. J. Natl. Cancer Inst. (Bethesda), 93: 39-45, 2001.
23. Brenner, A. J., Stampfer, M. R., and Aldaz, C. M. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene. 17: 199-205, 1998.
24. INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res., 58: 3508-3512, 1998.
25. Shay, J. W., Van der Haegen, B. A., Ying, Y., and Wright, W. E. The frequency of immortalization of human fibroblast and mammary epithelial cells transfected with SV40 large T-antigen. Exp. Cell Res., 209: 45-52, 1993.
26. Shay, J. W., and Wright, W. E. Quantitation of the frequency of immortalization of normal diploid fibroblasts by SV40 large T-antigen. Exp. Cell Res., 184: 109-118, 1989.
27. Ryu, T. (ed.). Biostastical Analysis, Ed. 4. Upper Saddle River. NJ: Prentice-Hall, Inc., 1999.
28. Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., and Evans, R. M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (Lond.), 358: 771-774, 1992.
29. Ouellette, M. M., Liao, M., Herbert, B. S., Johnson, M., Holt, S. E., Liss, H. S., Shay, J. W., and Wright, W. E. Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J. Biol. Chem., 275: 10072-10076, 2000.
30. Sporn, M. B., and Suh, N. Chemoprevention: an essential approach to controlling cancer. Nature Rev. Cancer, 2: 537-543, 2002.
31. Thun, M. J., Henley, S. J., and Patron, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. (Bethesda), 94: 252-266, 2002.
32. Singh, B., and Lucci, A. Role of cyclooxygenase-2 in breast cancer. J. Surg. Res, 108: 173-179, 2002.
33. Gala, M., Sun, R., and Yang, V. W. Inhibition of cell transformation by sulindac sulfide is confined to specific to oncogenic pathways. Cancer Lett., 175: 89-94, 2002.
34. Hwang, D., Scollard, D., Byrne, J., and Levine, E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. (Bethesda), 90: 455-460, 1998.
35. Gupta, R. A., and Dubois, R. N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Rev. Cancer, 1: 11-21, 2001.
36. Harris, R. E., Alshafie, G. A., Abou-Issa, H., and Seibert, K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res., 60: 2101-2103, 2000.
37. Rozic, J. G., Chakraborty, C., and Lala, P. K. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int. J. Cancer, 93: 497-506, 2001.
38. Thompson, H. J., Jiang, C., Lu, J., Mehta, R. G., Piazza, G. A., Paranka, N. S., Pamukcu, R., and Ahnen, D. J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res., 57: 267-271, 1997.
39. Berger, J., and Moller, D. E. The mechanisms of action of PPARs. Annu. Rev. Med., 53: 409-435, 2002.
40. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270: 12953-12956, 1995.
41. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Spiegelman, B. M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev., 8: 1224-1234, 1994.
42. Sporn, M. B., Suh, N., and Mangelsdorf, D. J. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol. Med., 7: 395-400, 2001.
43. Kopelovich, L., Fay, J. R., Glazer, R. I., and Crowell, J. A. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol. Cancer Ther., 1: 357-363, 2002.
44. Elstner, E., Müller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Herber, D., and Koeffler, H. P. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis in human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA, 95: 8806-8811, 1998.
45. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M. Terminal differentiation of human breast cancer through PPAR γ. Mol. Cell, 1: 465-470, 1998.
46. Kim, Y., Suh, N., Sporn, M., and Reed, J. C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem., 277: 22320-22329, 2002.
47. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
48. Foster, B. A., Coffey, H. A., Morin, M. J., and Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science (Wash. DC), 286: 2507-2510, 1999.
49. Rippin, T. M., Bykov, V. J. N., Freund, S. M. V., Selivanova, G., Wiman, K. G., and Fersht, A. R. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene, 21: 2119-2129, 2002.
50. Bykov, V. J., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., and Selivanova, G. Restoration of the tumor suppressor function to mutant p53 by a low- molecular-weight compound. Nat. Med., 8: 282-288, 2002.